Logo image of ESLA

ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Fundamental Analysis

NASDAQ:ESLA - US2975841048 - Common Stock

1.05 USD
+0.02 (+1.94%)
Last: 9/10/2025, 4:10:10 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ESLA. ESLA was compared to 541 industry peers in the Biotechnology industry. ESLA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ESLA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ESLA had negative earnings in the past year.
In the past year ESLA had a positive cash flow from operations.
In the past 5 years ESLA always reported negative net income.
ESLA had a negative operating cash flow in each of the past 5 years.
ESLA Yearly Net Income VS EBIT VS OCF VS FCFESLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -405.17%, ESLA is doing worse than 95.19% of the companies in the same industry.
Industry RankSector Rank
ROA -405.17%
ROE N/A
ROIC N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESLA Yearly ROA, ROE, ROICESLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

ESLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ESLA Yearly Profit, Operating, Gross MarginsESLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for ESLA has been increased compared to 1 year ago.
ESLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ESLA Yearly Shares OutstandingESLA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
ESLA Yearly Total Debt VS Total AssetsESLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ESLA has an Altman-Z score of -28.73. This is a bad value and indicates that ESLA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -28.73, ESLA is not doing good in the industry: 88.17% of the companies in the same industry are doing better.
There is no outstanding debt for ESLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Altman-Z -28.73
ROIC/WACCN/A
WACCN/A
ESLA Yearly LT Debt VS Equity VS FCFESLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 0.16 indicates that ESLA may have some problems paying its short term obligations.
ESLA has a Current ratio of 0.16. This is amonst the worse of the industry: ESLA underperforms 96.12% of its industry peers.
A Quick Ratio of 0.16 indicates that ESLA may have some problems paying its short term obligations.
The Quick ratio of ESLA (0.16) is worse than 95.93% of its industry peers.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.16
ESLA Yearly Current Assets VS Current LiabilitesESLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

ESLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.64%, which is quite impressive.
EPS 1Y (TTM)82.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-49.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 77.03% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-132.85%
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ESLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ESLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESLA Price Earnings VS Forward Price EarningsESLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

99.82% of the companies in the same industry are more expensive than ESLA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.22
EV/EBITDA N/A
ESLA Per share dataESLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

ESLA's earnings are expected to decrease with -67.60% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ESLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESTRELLA IMMUNOPHARMA INC

NASDAQ:ESLA (9/10/2025, 4:10:10 PM)

1.05

+0.02 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12
Earnings (Next)N/A N/A
Inst Owners1.7%
Inst Owner Change0.72%
Ins Owners2.22%
Ins Owner Change0%
Market Cap38.92M
Analysts82.86
Price Target16.32 (1454.29%)
Short Float %1.27%
Short Ratio8.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF 3.22
P/OCF 3.22
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)0.33
FCFY31.02%
OCF(TTM)0.33
OCFY31.02%
SpS0
BVpS-0.16
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -405.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.16
Altman-Z -28.73
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-49.71%
EPS Next Y-132.85%
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1159.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1159.11%
OCF growth 3YN/A
OCF growth 5YN/A